CA3133319A1 - Ghrh or analogues thereof for use in treatment of hepatic disease - Google Patents

Ghrh or analogues thereof for use in treatment of hepatic disease Download PDF

Info

Publication number
CA3133319A1
CA3133319A1 CA3133319A CA3133319A CA3133319A1 CA 3133319 A1 CA3133319 A1 CA 3133319A1 CA 3133319 A CA3133319 A CA 3133319A CA 3133319 A CA3133319 A CA 3133319A CA 3133319 A1 CA3133319 A1 CA 3133319A1
Authority
CA
Canada
Prior art keywords
ghrh
pharmaceutically acceptable
hexenoyl
trans
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133319A
Other languages
English (en)
French (fr)
Inventor
Steven K. Grinspoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CA3133319A1 publication Critical patent/CA3133319A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3133319A 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease Pending CA3133319A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (1)

Publication Number Publication Date
CA3133319A1 true CA3133319A1 (en) 2020-10-08

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133319A Pending CA3133319A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Country Status (10)

Country Link
US (4) US10799562B1 (cg-RX-API-DMAC10.html)
EP (1) EP3947426A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022527190A (cg-RX-API-DMAC10.html)
KR (1) KR20210145226A (cg-RX-API-DMAC10.html)
CN (1) CN113646327A (cg-RX-API-DMAC10.html)
AU (1) AU2020253828A1 (cg-RX-API-DMAC10.html)
CA (1) CA3133319A1 (cg-RX-API-DMAC10.html)
IL (1) IL286703A (cg-RX-API-DMAC10.html)
SG (1) SG11202110469PA (cg-RX-API-DMAC10.html)
WO (1) WO2020205498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CA3183299A1 (en) * 2020-07-05 2022-01-13 Christian Marsolais Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
EP3362053A4 (en) * 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
MX2018012716A (es) * 2016-04-19 2019-02-11 Griffon Pharmaceuticals Inc Peptidos bioactivos pegilados y usos de los mismos.
EP4467158A3 (en) * 2018-02-14 2025-02-19 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
JP2023548156A (ja) * 2020-10-30 2023-11-15 ザ ジェネラル ホスピタル コーポレイション 肝疾患の評価のためのキット、試薬、及び方法
WO2022104289A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis

Also Published As

Publication number Publication date
US10946073B2 (en) 2021-03-16
EP3947426A4 (en) 2023-01-04
US10799562B1 (en) 2020-10-13
WO2020205498A1 (en) 2020-10-08
KR20210145226A (ko) 2021-12-01
SG11202110469PA (en) 2021-10-28
CN113646327A (zh) 2021-11-12
US20200405816A1 (en) 2020-12-31
US20210177943A1 (en) 2021-06-17
US12233107B2 (en) 2025-02-25
JP2022527190A (ja) 2022-05-31
IL286703A (en) 2021-10-31
US20240091316A1 (en) 2024-03-21
US20200306345A1 (en) 2020-10-01
US11738066B2 (en) 2023-08-29
EP3947426A1 (en) 2022-02-09
AU2020253828A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
US12233107B2 (en) GHRH or analogues thereof for use in treatment of hepatic disease
JP2009001590A (ja) 短期及び長期の薬剤薬量決定のための方法
EP2209528A1 (en) Rapid acting injectable insulin compositions
US20050112093A1 (en) Combination therapy for HCV infection
MXPA04003238A (es) Metodo para tratar la infeccion de virus de hepatitis con una configuracion de suministro de interferon multifasica.
EP2763691A1 (en) Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
JP2017025086A (ja) 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
KR20040053291A (ko) 오메가 인터페론을 이용한 질환 치료 방법
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
EP3856767B1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
AU2020311050A1 (en) Stable formulations of recombinant proteins
KR20090020646A (ko) 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도
CN120693405A (zh) 降低一级预防受试者中重大不良心血管事件风险的方法
US20040223951A1 (en) Combination therapy for cancer
US20200197494A1 (en) Peptide compositions and methods of use
EP4643862A1 (en) Pharmaceutical composition and use thereof
US20130079416A1 (en) Homeopathic medicament comprising phenacetin for the treatment of cancer
CN119345327A (zh) 双受体激动剂在结直肠癌治疗中的用途
CN117018197A (zh) 促进dock11表达的试剂作为治疗神经病理性疼痛药物的应用
Bavec Insulin, Other Hypoglycaemic Drugs, and Glucagon
AU2011265228A1 (en) Methods of mitigating effects of radiation and reducing the risk of systemic infection
NZ710730A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
WO2015036507A1 (en) Use of cabazitaxel in patients with metastatic nsclc progressing after docetaxel-based treatment
HK1129840A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20251003

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251003

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112